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Back pain is a common and costly health problem worldwide. There is yet a lack of consis-
tent methodologies to estimate the economic burden of back pain to society.
Objective
To systematically evaluate the methodologies used in the published cost of illness (COI) lit-
erature for estimating the direct and indirect costs attributed to back pain, and to present a
summary of the estimated cost burden.
Methods
Six electronic databases were searched to identify COI studies of back pain published in
English up to February 2021. A total of 1,588 abstracts were screened, and 55 full-text stud-
ies were subsequently reviewed. After applying the inclusion criteria, 45 studies pertaining
to the direct and indirect costs of back pain were analysed.
Results
The studies reported data on 15 industrialised countries. The national cost estimates of
back pain in 2015 USD ranged from $259 million ($29.1 per capita) in Sweden to $71.6 bil-
lion ($868.4 per capita) in Germany. There was high heterogeneity among the studies in
terms of the methodologies used for analysis and the resulting costs reported. Most of the
studies assessed costs from a societal perspective (n = 29). The magnitude and accuracy of
the reported costs were influenced by the case definition of back pain, the source of data
used, the cost components included and the analysis method. Among the studies that pro-
vided both direct and indirect cost estimates (n = 15), indirect costs resulting from lost or
reduced work productivity far outweighed the direct costs.
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Conclusion
Back pain imposes substantial economic burden on society. This review demonstrated that
existing published COI studies of back pain used heterogeneous approaches reflecting a
lack of consensus on methodology. A standardised methodological approach is required to
increase credibility of the findings of COI studies and improve comparison of estimates
across studies.
Introduction
Cost of illness (COI) studies aim to identify and measure the economic impact of an illness
including the direct and indirect costs [1, 2]. These studies are descriptive, and they quantify
the costs without comparing alternative uses of healthcare resources. COI studies can, how-
ever, serve as a basis for further economic evaluations and they are particularly useful for
chronic diseases that impact heavily on health expenditures [3, 4].
Back pain is a common health problem and is the leading cause of years lived with disability
in most countries and age groups [5–7]. Although back pain has low impact in terms of mor-
tality, it imposes great medical and non-medical related costs on patients, employers, and
health care providers [1, 8, 9]. As society is aging worldwide, these costs are likely to rise put-
ting further pressure on health care services.
Despite the substantial costs reported in COI studies of back pain, there is little guidance in
the literature to support the choice of methodologies in those studies. Dagenais et al. [1] con-
ducted a systematic review of COI studies in LBP focussing on the magnitude of the economic
burden rather than the methodologies. Their review from 2007 was restricted to one biomedi-
cal database (Medline) and examined only studies published in the previous 10 years. In the
intervening years, a number of studies have emerged across many countries. There is a clear
lack of consensus about the appropriate methodologies to use to estimate the economic impact
of back pain. The objective of this review was to systematically gather and characterise the
body of literature on the direct and indirect costs of back pain in order to evaluate the method-
ological approaches used by researchers in developing COI studies of back pain. We also pres-
ent the resulting national estimates of direct and indirect costs of back pain from the reviewed
studies.
Methods
We conducted a systematic scoping review guided by the framework introduced by Arksey
and O’Malley [10], and following the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [11] guidelines for reporting.
Search strategy
Six electronic databases (MEDLINE, Embase, CINAHL Plus, Web of Science, EconLit, and
Centre for Reviews and Dissemination (CRD)) were searched for studies published in English
from inception to February 2021. We focussed the search on OECD countries where access
and structure of the healthcare systems are more comparable amongst these high-income
countries. The literature searches were conducted using a combination of keyword searching
and medical subject headings (MeSH). The searches were made robust by making use of wild-
cards, phrase searching and truncation of the search terms as appropriate (S1 File). Only full
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text articles were considered ensuring that studies with sufficient methodological detail were
assessed.
Inclusion and exclusion criteria. Studies had to meet the following inclusion criteria:
1. Conducted in the UK and other high income countries (OECD members [12]).
2. Concerned with economic burden of back pain or low back pain.
3. Cost provided as monetary estimate of direct or indirect costs.
4. Studies investigating adult patients.
5. Reports written in English.
The exclusion criteria used were as follows:
1. Musculoskeletal conditions other than back pain.
2. Economic evaluations of interventions.
3. Review articles.
4. Abstracts or conference proceedings.
Selection of studies for review. Eligibility of the identified studies was assessed using a
two-stage categorisation process (Table 1) that have been described in detail elsewhere [13–
15]. The categorisation process was designed to be as inclusive as possible so that no study fell
outside of the predefined groups. One reviewer (DZ) screened studies initially by title and then
categorised them into six groups (A-F). This was followed by full text reading of potentially
Table 1. Categorisation process for selection of studies for review.
Stage I—Initial categorisation of studies:
A. The study reports primary or secondary research on the economic burden of back pain and provides
substantial cost data.
B. The study discusses the cost of back pain and provides estimates of some aspects of COI or components of
direct or indirect costs.
C. The study provides useful information on assessing the economic burden of back pain but does not entirely
fall into either A or B. (e.g. methodological studies on COI without reporting direct or indirect costs estimates).
D. The study discusses general aspects of the economic impact of back pain but provides little or no data on
direct or indirect costs (e.g. economic evaluations).
E. Full text of the study is not available (abstracts, conference proceedings).
F. The study does not have any relevance to the economic burden of back pain.
Studies in category (A), (B) or (C) will deemed relevant for the systematic review while those in category (D), (E) or
(F) were excluded at this stage.
Stage II—Further categorisation of studies:
1. Cost of illness (COI) analysis studies (direct or indirect cost)
2. Other cost studies
3. Description of methods used in assessing cost of back pain
4. Private out of pocket expenditure
5. Economic evaluations
6. Review articles without new data
7. Not relevant for economic burden of back pain.
Studies classified as A(1), A(2), B(1) and B(2) were determined to be suitable for data extraction. Studies coded as C
(3) and ABC(6) were retained for background literature and discussion purposes. All other studies not classified into
one of the above categories were excluded.
https://doi.org/10.1371/journal.pone.0251406.t001
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relevant studies and further classified them into eight groups (1–8). A second reviewer (JK)
retrieved and reviewed a random sample of 25% of the studies at each stage of the selection
process to assess agreement. Any discrepancies were resolved by discussion until a consensus
was reached by all five authors. We did not exclude papers on quality grounds as the purpose
of the review was to identify the range of methods that have been used to estimate the cost of
back pain and to identify the entire range that has been apportioned to back pain, in order to
inform a planned primary study.
For each study, a range of data including study characteristics, methodology used, and the
results reported were extracted using an electronic template. The information was tabulated,
and the methodology and findings of individual studies were compared narratively. For con-
sistency and standardisation across studies, all costs were converted to 2015 US dollars using
country-specific gross domestic product inflator index and purchasing power parity (PPP)
conversion [16].
Results
The search identified a total of 8,009 potential citations. After removing duplicates and title
screening of the citations, 1,588 studies reached the initial categorisation stage. Following the
initial categorisation by title and abstract, 55 studies were included in the second stage of the
review process. These articles were read in full and further classified to determine their suit-
ability for inclusion resulting in a total of 45 studies coded A(1), A(2), B(1), and B(2) that met
the criteria for the review (Fig 1).
The 45 studies included 17 studies (39%) from the United States [17–33], five (11%) from
Sweden [34–38], four (9%) from The Netherlands [39–42], and three (7%) each from the UK
[9, 43, 44], Germany [45–47], and Japan [48–50] (Table 2). The studies were published from
1995 to 2020, and the data collection spanned from 1987 to 2017. The age of data at the time of
publication in the reviewed studies ranged from one year [30] to 11 years [18, 28]. There was
also high heterogeneity among the studies in terms of the methodologies used for analysis and
the resulting cost estimates reported.
The main methodological characteristics of the included studies are summarised below. A
general description of the introductory concepts and approaches used in COI studies is first
given (Table 3).
Back pain diagnostic criteria
International Classification of Diseases codes (ICD-9 or ICD-10 codes) or a variant of these
were typically used to define back pain by over half of the studies, while self-reported back
pain assessment was reported in 15 studies [18–20, 26, 28, 35, 39, 45, 47, 49, 51–55]. The diag-
nostic criteria used was not explicitly specified in some of the studies [19, 30, 50, 56, 57]. How-
ever, studies with diagnostic codes were often used to produce national cost estimates
compared to studies with self-reported or non-specific back pain definition types that mainly
provided either average costs per patient or indirect cost estimates.
Source of data
A diverse range of data sources were used including surveys, national databases, compensation
claims and cost diaries. Multiple sources of data were typically used in many of the studies,
and the reported direct or indirect costs were the result of combining and summing an array
of data sources. Large-scale surveys, and claims databases dominated the source of utilisation
data with the latter being used mainly in insurer perspective studies. The use of electronic
health records (EHRs) and registry data was limited [34, 37, 38, 41, 43]. In the US, the Medical
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Expenditure Panel Survey (MEPS) database was the single most common source of data for
analysing COI for back pain [22, 24, 28, 29].
Perspective of the analysis
The societal perspective which is preferred since it is the most comprehensive perspective was
adopted by the majority of the studies (n = 29) while only two studies followed a healthcare
perspective [43, 51]. Taking the viewpoint of insurance-based health care, the insurer perspec-
tive was the second most popular [17, 20, 21, 23, 25, 27, 31, 32, 46, 50, 56] perspective. It was
apparent that most of the insurer perspective studies (9 out of 12) were US studies [17, 20, 21,
23, 25, 27, 31–33] conducted using claims databases. Cost analysis from industry or employer
perspective is limited in its scope and was less common [18, 19].
Cost components
No significant methodological differences were observed between studies that assessed both
direct, and indirect costs (n = 23) and those that reported on direct costs only [17, 21–23, 25,
27, 29, 31, 43, 46, 48, 51, 56] or indirect costs only [18, 20, 26, 28, 30, 40, 44]. This review
Fig 1. PRISMA diagram of literature search and study selection.
https://doi.org/10.1371/journal.pone.0251406.g001
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Walker, 2003 Australia/Societal National R, PB Australian adult LBP prevalence
survey, 2001









Coyte, 1998 Canada/Societal National R, PB Ontario Health Survey data, 1990–
94
Diagnostic code Top-down Human capital
Hemmila, 2002 Finland/Societal Regional R, PB Social Insurance Institution files,
and patient records, 1994




National R, PB Surveys/questionnaires, 2001 Self-reported Bottom-up n/a
Muller-Schwefe,
2011
Germany/Insurer Health insurer� 5.2
million members
R, IB German statutory health insurance
fund (DAK) claims data, 2006
Diagnostic code Bottom-up n/a
Wenig, 2009 Germany/Societal National R, PB Postal survey by German Back
Pain Research Network (GBPRN),
2003–06
Self-reported Bottom-up Human capital
Becker, 2010 Germany/Societal Regional P, PB Cross sectional sample from an
RCT, 2004
Self-reported Bottom-up Human capital
Watson, 1998 Isle of Jersey/
Societal





Japan/Societal National R, PB Japan National Health &




Itoh, 2013 Japan/Societal National R, PB Survey of Medical Care Activities
in Public Health Insurance, 2011
Diagnostic code Bottom-up n/a
Shinohara, 1998 Japan/Insurer National R, PB Labour Standards Inspection









Olafsson, 2018 Sweden/Societal Regional R, PB Administrative database VEGA,
2008–11
Diagnostic code Bottom-up Human capital
Ekman, 2005 (b) Sweden/Societal Regional R, PB Surveys/questionnaires, 2002 Self-reported Bottom-up Human capital
Ekman, 2005 (a) Sweden/Societal National R, PB Survey and registry data, 2001 Diagnostic code Top-down human capital
Hansson, 2005 Sweden/Societal Regional P, PB Prospectively entered diaries and
questionnaires, 1994–95
Diagnostic code Bottom-up Human capital
Jonsson, 2000 Sweden/Societal National R, PB, IB National Board of Health and
Welfare’s register, 1994
Diagnostic code Top-down Human capital
Wieser, 2011 Switzerland/
Societal
Regional R, PB Large population-based survey,
2005




National R, PB National registries and authorities,
2007
Diagnostic code Top-down Human capital
Boonen, 2005 Netherlands
/Societal
National P, IB Cost diaries from three cohorts,
2002
Self-reported Bottom-up Friction cost
van Tulder, 1995 Netherlands/
Societal
National R, PB Survey and registry data, 1991 Diagnostic code Top-down Human capital
Hutubessy, 1999 Netherlands/
Societal
National R, PB Social Insurance Council data,
1991




Spain/Societal National R, PB National Health Survey of 2017
(NHS 2017), 2017
Self-reported Bottom-up Human capital
Yumusakhuylu,
2018
Turkey/Societal National R, n/s Surveys/questionnaires, 2011 Other/non-
specific
Bottom-up Human capital
Icatasiotlu, 2015 Turkey/Societal National R, PB Surveys/questionnaires, 2013 Self-reported Bottom-up Human capital
Hong, 2012 UK/Health-care
provider
National CC, PB UK General Practice Research
Database (GPRD), 2007–09
Diagnostic code Bottom-up n/a
(Continued)
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examined the cost components reported with the aim of identifying the most important cost
drivers. For direct costs, studies reporting all three major components of inpatient, outpatient,
and pharmaceutical costs were summarised for comparison (Fig 2). Outpatient cost was the
most important cost driver in the majority of the studies, followed by inpatient cost.
For indirect costs, this review compared studies reporting at least two of the three major
cost components of absenteeism, presenteeism and early retirement (Fig 3). Absenteeism
which was assessed in all the studies compared was the most relevant cost driver in most stud-
ies. Although presenteeism was only assessed in five of the studies, it was found to be the most















Maniadakis, 2000 UK/Societal National R, PB Office of Population Censuses and
Surveys (OPCS), 1997
Diagnostic code Top-down Human capital
& Friction cost
Kim, 2019 USA/Insurer Health insurer� 75
million members
R, PB MarketScan Commercial Claims
Database, 2007–16
Diagnostic code Bottom-up n/a
Smith, 2013 USA/Societal National R, PB Medical Expenditure Panel Survey
(MEPS), 2000–07
Diagnostic code Bottom-up n/a
Martin, 2008 USA/Societal National CC, PB Medical Expenditure Panel Survey
(MEPS), 2005
Diagnostic code Bottom-up n/a
Mehra, 2012 USA/Insurer Large regional health
insurer
CC, PB PharMetrics IMS LifeLink claims
database, 2006–08
Diagnostic code Bottom-up n/a
Gore, 2012 USA/Insurer Health insurer� 62
million members
CC, IB LifeLink Health Plan Claims
Database, 2008
Diagnostic code Bottom-up n/a
Ricci, 2006 USA/Societal National R, PB Caremark American Productivity
Audit (telephone survey), 2003–04
Self-reported n/a Human capital





Lind, 2005 USA/Insurer Two Washington State
companies
R, PB Health insurance claims data from
insurance companies, 2002
Diagnostic code Bottom-up n/a
Mapel, 2004 USA/Insurer Health insurer with
240,000 members
CC, PB Lovelace Health Plan (LHP)
administrative databases, 2000–01
Diagnostic code Bottom-up n/a
Vogt, 2005 USA/Insurer Health insurer with
255,958 members
R, PB UPMC Health Plan claims
database, 2001
Diagnostic code Bottom-up n/a
Ritzwoller, 2006 USA/Insurer Health insurer
with > 410,000
members
R, IB Keiser Permanente Colorado
(KPCO) claims database, 1996–
2001
Diagnostic code Bottom-up n/a
Luo, 2004 USA/Societal National CC, PB Medical Expenditure Panel Survey
(MEPS), 1998
Diagnostic code Bottom-up n/a
Rizzo, 1998 USA/Societal National R, PB National Medical Care
Expenditure Survey (NMES), 1987
self-reported n/a Human capital
Hashemi, 1998 USA/Insurer Insurer with 10% of
WC market
R, IB Claims data from a large insurer,
1996
Self-reported n/a n/s
Guo, 1999 USA/Employer US industries R, PB National Health Interview Survey
(NHIS), 1988
Self-reported n/a n/s
Williams, 1998 USA/Insurer Regional WC insurer R, n/s Detailed Claim Information (DCI)
database, 1988–92
Diagnostic code Bottom-up n/s
Gustafson, 1995 USA/Employer Four participating
hospitals
P, n/s Employer records, 1991–92 Self-reported Bottom-up n/s
n/a = not applicable, n/s = non-specific, P = prospective, R = retrospective, PB = prevalence based, IB = incidence based, CC = matched case-control
LBP = low back pain, RCT = randomised controlled trial, WC = workers compensation, UPMC = University of Pittsburgh Medical Centre
https://doi.org/10.1371/journal.pone.0251406.t002
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Estimating resource utilisation
The bottom-up approach was a commonly adopted method (n = 29) to calculate the direct
costs of back pain compared to the top-down approach [9, 34, 37, 41, 42, 57–59]. The top-
down approach was preferred in studies where cost data were widely available from national
health statistics. Cost estimations were more detailed in bottom-up studies since individual-
level data were aggregated to get the population-level estimates. However, the application of an
incremental cost method using a matched-control or econometric methods was limited [17,
22–25, 43].
Indirect cost estimation
The human capital (HC) approach was typically applied [26, 28, 30, 34–38, 41, 42, 45, 47, 49,
52, 53, 55, 58, 60] in studies that estimated the indirect costs of back pain. The use of both HC
and friction cost (FC) approaches was limited [9, 40, 54, 59]. In studies that applied both meth-
ods, the HC approach resulted in significantly higher estimates of the indirect costs of back
pain. Hutubessy et al. [40] reported the indirect costs of back pain in The Netherlands in 1991
to be $1.5 billion using the FC method; but this increased by three-fold to $4.6 billion under
the HC approach.
The annual national cost estimates of back pain from 26 studies that reported national esti-
mates are summarised in Table 4. The total cost estimates in 2015 USD ranged from $259 mil-
lion ($29.1 per capita) in Sweden to $71.6 billion ($868.4 per capita) in Germany. Direct
comparison of costs between the studies is not feasible due to significant differences in the
methodologies adopted. In studies that provided both direct and indirect cost estimates
Table 3. Main concepts and approaches used in COI studies.
Type of approaches/Concepts Description
Cost categories: Direct and indirect costs Direct medical cost: Costs directly related to the disease.
Consultations, hospitalisation, medication, diagnostic tests, and
accident and emergency services.
Indirect cost: Costs due to lost or reduced productivity caused by the
disease. Work absence resulting in lost productivity (termed
‘absenteeism’), and decreased productivity for those who continue
to work (termed ‘presenteeism’).
Epidemiological approaches: Prevalence-
based Vs. incidence based
Prevalence-based: Evaluates costs for all existing cases in a given
period.
Incidence-based: Evaluates costs by assessing the number of new
cases in a given period.
Cost perspectives: Societal, health system,
industry, individual perspective
The perspective of the analysis indicates who bears the costs, which
in turn determines which costs are to be included in the analysis.
Resource estimation: Top-down Vs. bottom-
up approaches
Top-down: Measures the proportion of cost attributed to a disease
from aggregate figures. Analysis directed from total to lower levels.
Bottom-up: Based on actual consumption of resources by referring
to records of patients. Analysis directed from individual levels to
the total.
Indirect cost estimation: Human capital Vs.
friction cost methods
Human capital (HC): Productivity losses are approximated by the
value of the individual’s earnings assuming that the person would
have continued to work in full health.
Friction cost (FC): Uses what is known as the friction period which
is the time until another individual from the unemployment pool
replaces the worker who is absent due to sickness. The value of
productivity losses is then estimated on the basis of the individual’s
earnings over the friction period.
https://doi.org/10.1371/journal.pone.0251406.t003
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(n = 15), indirect costs generally far outweighed the direct costs (S2 File). Measures of preci-
sion or dispersion such as confidence intervals or standard deviations around cost estimates
were rarely reported in the included studies, and those that reported were largely limited to
studies that applied econometric methods for cost estimation [17, 23, 24, 43]. In addition, the
measures given were generally for the sample estimates (average resource use or cost) rather
than for the extrapolated national cost estimates. This review also uncovered that sensitivity
analysis is often not conducted in COI studies with only few studies [9, 24, 39, 43, 47, 54, 58,
59] performing any sensitivity analysis. Moreover, the use of an alternative cost estimation
method was considered only in a minority of the studies [9, 24, 40, 54, 59] but resulted in con-
siderably different estimates, particularly for indirect costs. Irrespective of the analysis method
used, the reported results reveal the significant economic burden of back pain on healthcare
systems and society as a whole.
Fig 2. Allocation of direct costs in COI studies of back pain. Legend: The figure illustrates the allocation of direct
costs in studies that reported on all three major costs components (inpatient, outpatient, and pharmaceutical costs) of
direct costs.
https://doi.org/10.1371/journal.pone.0251406.g002
Fig 3. Allocation of indirect costs in COI studies of back pain. Legend: The figure illustrates the allocation of
indirect costs in studies that reported on at least two of the three major costs components (absenteeism, presenteeism,
and early retirement costs) of indirect costs.
https://doi.org/10.1371/journal.pone.0251406.g003
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Discussion
This review examined 45 COI studies with the aim of assessing the methodologies used to esti-
mate direct and indirect costs associated with back pain. The findings of the review indicated
that there is little consensus in the methodologies used to derive cost estimates for back pain,
and the reported costs were substantial and wide-ranging.
Summary of findings
Findings from the included studies confirm that back pain is a costly problem worldwide. The
national cost estimates ranged from $259 million to $71.6 billion. It was clear from the studies
Table 4. National estimates of direct, indirect, and total costs of back pain.
Ref. Country Population (million) Direct costs Indirect costs Total costs
National (million $) % Per capita National (million $) % Per capita National (million $) Per capita
[34] Sweden 8.9 42 16 4.7 217 84 24.4 259 29.1
[36] Sweden 8.9 61 15 6.9 346 85 38.9 407 45.7
[38] Sweden 9.4 261 33 27.7 527 67 56.0 788 83.7
[57] Belgium 10.2 302 16 29.5 1,603 84 156.7 1,905 186.2
[41] Netherlands 16.4 622 13 38.0 4,014 87 245.1 4,636 283.0
[55] Spain 46.5 3,380 25 72.6 9,878 75 212.3 13,257 284.9
[48] Japan 127.8 26,699 69 208.9 11,866 31 92.8 38,565 301.8
[58] Canada 29.1 832 8.3 28.6 9,209 92 316.4 10,041 344.9
[9] UK 58.5 3,363 13 57.5 22,015 87 86.7 25,378 433.9
58.5 3,363 25 57.5 �10,358 75 177.1 13,721 234.6
[37] Sweden 8.8 130 3.3 14.8 3,799 97 432.7 3,929 447.5
[59] Australia 19.4 1,058 11 54.5 8,400 89 432.8 9,458 487.3
19.4 1,058 17 54.5 �5,220 83 268.9 6,278 323.4
[42] Netherlands 15.1 586 7.4 38.9 7,319 93 485.7 7,905 524.6
[39] Netherlands 16.2 6,101 66 377.8 3,206 34 198.5 9,307 576.3
[54] Switzerland 7.4 2,109 39 283.5 3,326 61 447.0 5,435 730.5
7.4 2,109 54 283.5 �1,785 46 239.9 3,894 523.4
[47] Germany 82.5 33,176 46 402.3 38,438 54 466.1 71,614 868.4
[48] Japan 127.8 791 na 6.2 na na na na na
[56] Korea 46.0 564 na 12.3 na na na na na
[43] UK 62.3 4,457 na 71.6 na na na na na
[24] USA 295.5 39,000 na 132.5 na na na na na
295.5 ~102,000 na 346.9 na na na na na
[22] USA 275.9 126,258 na 457.6 na na na na na
[26] USA 292.8 na na na 9,115 na 31.1 na na
[44] Jersey 0.1 na na na 3 na 36.6 na na
[18] USA 266.3 na na na 20,287 na 76.2 na na
[28] USA 287.6 na na na 25,559 na 88.9 na na
[28] USA 269.4 na na na 40,318 na 149.7 na na
[40] Netherlands 15.1 na na na 7,339 na 487.0 na na
15.1 na na na �2,387 na 158.0 na na
� Estimated with alternative friction cost (fc) approach for the study above
~ Estimated with alternative incremental cost method for the study above
All costs are presented in 2015 USD.
https://doi.org/10.1371/journal.pone.0251406.t004
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reviewed that indirect costs were the main cost drivers for back pain and consequently, major
cost savings could be obtained from interventions that bring about early return to work and
reduce productivity losses. Outpatient costs were the main cost drivers of direct costs, while
absenteeism represented the largest share of indirect costs. However, in the case of indirect
costs, our review indicated that presenteeism is often underexplored but represents a signifi-
cant proportion of the indirect costs of an illness. The significance of presenteeism for the
value of lost production were also highlighted in previous literature [54, 61, 62]. A sound
methodological framework for the assessment of presenteeism poses a challenge, but the
potential impact of presenteeism on costs needs to be included in order to improve the reliabil-
ity of results [61, 62].
Several factors were likely to have influenced the magnitude and accuracy of the estimates
reported. Comparing and generalising these quantitative results is problematic because signifi-
cantly different approaches had been adopted to estimate the economic burden of back pain.
The validity of each method would be related to the available data and the proposed use of the
findings. Hence, this review did not find any particular features that should be absolutely
avoided to generate valid data. Almost all studies that assessed direct costs reported costs relat-
ing to inpatient, outpatient, and pharmaceutical costs; however, few studies included costs
relating to emergency department, occupational therapy, or allied health care. Similarly, only
few studies included all three major components of indirect costs potentially indicating lack of
data source or standardised instruments for the assessment of some indirect cost components.
Hence, a wide range of estimates were found across the included studies both nationally and
internationally.
Key methodological challenges
The discrepancies in reported costs and methodologies did not appear to be attributed to the
cost perspective taken since most studies adopted the societal perspective. The main sources of
variations in the methodologies used in COI studies of back pain were the way in which back
pain was defined, the sources of data used, the cost components included, and the approaches
used to estimate both direct and indirect costs (e.g. Top-down vs. bottom-up or human capital
vs. friction cost methods). There were also considerable discrepancies between the year of data
used and the year of publication which should be carefully considered in order to avoid draw-
ing conclusions from outdated data. Quantitative estimates reported should therefore be inter-
preted with caution taking into account any changes that may have taken place in the time
period between pricing and publication.
Diagnosis of back pain should ideally be on clearly defined criteria so that studies might be
comparable and replicated as necessary. Consensus on criteria and assessment of the reported
cases may be a practical solution for addressing the discrepancies in case definitions [63]. The
main data sources reported for direct cost estimates were large surveys and insurance claims
databases. Self-reported measures for healthcare resource utilisation are known to have limita-
tions with validity of the data due to recall bias [64, 65]. Since many episodes of back pain are
recurrent and short lived [66], resource utilisation may crucially be under-reported in survey-
based studies. In studies using insurance claims data, the claims might be subject to co-pays,
and deductibles or the insurance coverage may vary from plan to plan or from employer to
employer. Moreover, since cost estimations are conducted in relation to insured individuals,
generalisation of the findings to the wider population may not be appropriate.
The number and type of cost components reported in the studies were highly heteroge-
neous for both the direct and indirect cost categories. Some studies focussed only on major
cost components of consultations, prescriptions, and hospitalisations, whereas others also
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considered services such as diagnostic imaging, physiotherapy, and accident and emergency.
This meant that significant discrepancies existed in reported costs, and studies with partial
estimates of healthcare costs could not be compared with those reporting full COI estimates.
The way in which healthcare resource utilisation is valued could also impact on the reported
costs. Most studies used a direct method of summing up back pain related costs which under-
estimated the true cost of back pain compared to an incremental cost approach. The incremen-
tal approach was more comprehensive and accounted for costs that would otherwise have
been missed such as costs due to comorbidities resulting from back pain. Valuation of indirect
costs using the human capital and friction cost approaches also resulted in widely different
estimates with the HC method consistently producing significantly higher costs than the FC
method. However, unlike the direct cost estimation methods, the justification for the choice of
one method over the other is not clear and there is ongoing debate as to the best method [67–
69]. A review and assessment of the evidence suggests that a pragmatic approach is to use both
the HC and FC approaches as sensitivity analyses [70].
Strengths, limitations, and comparison with other studies
This is the first review aimed at assessing the methodologies used in COI studies of back pain.
The previous review [1], which focussed on synthesising results rather than methodologies,
was from 2008 and the findings were slightly limited by only including studies published in
the previous 10 years. A major strength of this review was that large number of studies were
included that varied greatly by country and methodology, and the search was conducted with
no restriction on publication date. Methodological differences that may not always be apparent
but resulting in significant influence on COI estimates of back pain were revealed by this
review. A potential limitation was that this review only considered studies conducted in devel-
oped countries and published in English. Nevertheless, the findings of this review can be con-
sidered robust given that such a large number of studies were examined.
It was noteworthy that several studies did not explicitly describe their methodologies posing
challenges to assess them. This lack of clarity is also confirmed by other systematic reviews [1,
71–73], and appears to be a common feature of COI studies. There was also a lack of consensus
and guideline on the use of methodologies which may make the analyses prone to underesti-
mation or overestimation of the true costs of the illness. This finding is consistent with that of
other systematic reviews of COI analyses, and was not restricted to back pain [74–77]. Another
limitation was that the studies did not explicitly report on costs of complications such as revi-
sion surgery for infection which are a major source of treatment costs post-surgery. No such
distinction was made between costs due to complications and other costs. Furthermore, sensi-
tivity analysis does not appear to be a standard practice in current COI studies with only a
minority of studies conforming to the norm. Sensitivity analysis is also rarely done in COI
studies of other conditions [72, 74].
Key implications and recommendations
The lack of standardised and validated instrument and research methodology in COI studies
meant that researchers must be careful with their terminology, data source, and methodology
used for estimation. Certain types of approaches might be more appropriate than others which
has implications for replicating and validating a specific study. The methodological consider-
ations highlighted in this review offer practical guidance to researchers, decision makers, and
funders in designing future COI studies. The trade-offs in the various methodological options
available for performing the calculations and their effects on the resulting cost estimates should
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not be underestimated. Stakeholders should consider what degree of accuracy is required in
COI analysis to ascertain the appropriate methods that will meet decision makers’ needs.
Based on the findings of this review, some important recommendations for good practice
can be drawn which may help produce more reliable estimates for the costs of back pain with
implications for COI studies in general:
• As back pain imposes an enormous economic burden, costs must be estimated more accu-
rately and inclusively, and a bottom-up approach using an incremental cost method is rec-
ommended as base case analysis.
• Identification of cases should be based on a broad consensus on case definition of back pain,
and the use of diagnostic codes is preferred.
• Resource utilisation may be better estimated by following up a large sample of patients from
electronic health records, and valuation of unit costs should be carefully assessed.
• Patient characteristics, such as comorbidities, should be clearly reported. Where appropriate,
separate cost estimates need to be reported for subgroups of patients.
• Researcher should test the sensitivity of the analysis, give detailed descriptions, and discuss
limitations of the methodological choices.
• Finally, development of guideline and standardisation of the methodologies used for COI
studies may not only enhance the reliability and interpretation of the estimates, but it also
enables comparability of the results across studies.
Conclusions
COI studies may provide important information and serve as a basis for further economic
evaluations and allocation of resources. In the absence of widely accepted standards and con-
sensus on methodology, conducting a COI study capable of identifying and measuring the
true cost of an illness remains a challenge. Methodological variations and the discrepancies
that arise within them have direct impact on the comparability and credibility of COI studies.
This review has reported a widespread heterogeneity in the methodologies used, and the sub-
stantial direct or indirect cost estimates produced for back pain. By informing the relative
importance of this health problem, the information obtained here has important implications
on the allocation of scarce resources and other health policy decision making.
This review also highlighted some factors that might have substantial impact on the
reported cost estimates. Recommendations about good practice for COI studies of back pain
have been suggested based on the findings of this review. These recommendations may help
obtain reliable estimates of the true cost of the illness, improve the quality and reporting of the
analysis, and provide validity to COI studies.
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